Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inmune Bio (INMB) Revenue (2021 - 2025)

Historic Revenue for Inmune Bio (INMB) over the last 5 years, with Q1 2025 value amounting to $50000.0.

  • Inmune Bio's Revenue rose 25714.29% to $50000.0 in Q1 2025 from the same period last year, while for Sep 2025 it was $50000.0, marking a year-over-year increase of 1904.76%. This contributed to the annual value of $14000.0 for FY2024, which is 9096.77% down from last year.
  • As of Q1 2025, Inmune Bio's Revenue stood at $50000.0, which was up 25714.29% from $14000.0 recorded in Q1 2024.
  • In the past 5 years, Inmune Bio's Revenue ranged from a high of $163000.0 in Q4 2021 and a low of $4000.0 during Q1 2021
  • For the 5-year period, Inmune Bio's Revenue averaged around $59538.5, with its median value being $43000.0 (2023).
  • As far as peak fluctuations go, Inmune Bio's Revenue soared by 397500.0% in 2022, and later plummeted by 7668.71% in 2023.
  • Over the past 5 years, Inmune Bio's Revenue (Quarter) stood at $163000.0 in 2021, then crashed by 40.49% to $97000.0 in 2022, then crashed by 71.13% to $28000.0 in 2023, then tumbled by 50.0% to $14000.0 in 2024, then skyrocketed by 257.14% to $50000.0 in 2025.
  • Its Revenue was $50000.0 in Q1 2025, compared to $14000.0 in Q1 2024 and $28000.0 in Q4 2023.